Menu

Electrophysiological and Clinical Effects of Walking Downhill in Stroke Patients

Status

Not yet enrolling

Conditions

Stroke

Treatments

Procedure: Downhill walking
Procedure: Walking on flat ground

Study type

Interventional

Funder types

Other

Identifiers

NCT05833295
MAR.FTR.ST

Details and patient eligibility

About

investigation of the effects of walking for 20 minutes on the acute H/M ratio on flat ground, downhill slopes at -7.5 degrees and -15 degrees in patients who have had a stroke, have spasticity and are ambulatory.

At the same time, the aim of the study is to obtain the clinical effectiveness of this walking pattern and control of the H/M ratio by checking the H/M ratio again after 5 sessions and 20 minutes of walking for the patients participating in the study.

Full description

Participants will wear a seat belt connected to an overhead support and will walk on a treadmill with a dual-band instrument at a sampling frequency of 2000 Hz. The seat belt will only serve as a safety mechanism in case of a fall and will not support any body weight while walking. Each participant will walk for 20 minutes under one of 3 slope conditions; treadmill walking on 0° flat ground, , downhill walking with treadmill on -7.5° slope and downhill walking with treadmill on -15° slope.

First, by asking the participants to walk at their comfortable speed for straight walking on the treadmill with tools, the walking speed will be determined and carried out at the specified speeds. All self-selected walking speeds will be determined in two 30-second trials. During the 20-minute walk for each condition, if the participant needs to slow down, the speed of the treadmill will be reduced to adapt to this, and the average walking speed during the 20-minute walking session will be reported. Pulse and blood pressure will be monitored before, during and after the walk.

All participants will be evaluated with modified asworth scale, modified tardeu scale, 2 minute walking test, modified rankin scale, timed get up and walk test, fatigue impact scale, stroke impact scale, berg balance scale, fugl meyer assessment scale before treatment.

Patients will be randomized into 3 groups. Then, the H / M ratio will be looked at in all 3 groups. After the first walking session, the H / M ratio will be repeated. after completing the 5-session walking program, clinical and electrophysiological tests will be repeated.

Enrollment

21 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients diagnosed with stroke between the ages of 18 and 65 Dec

Exclusion criteria

  • Other neurological disorders,

    • Expressive or receptive aphasias,
    • Severe heart disease,
    • A history of poorly controlled diabetes,
    • Active cancer,
  • Those who have been injected with botilinum toxin in the last 3 months,

    • Orthopedic conditions affecting the legs, a history of hip or knee replacement,
    • Serious simultaneous medical problems, such as peripheral nerve damage
  • Inability to comprehend verbal instructions

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

21 participants in 3 patient groups

Walking on flat ground
Experimental group
Description:
Patients will walk for 20 minutes at a 0% slope.
Treatment:
Procedure: Walking on flat ground
-%7.5 Downhill walking
Experimental group
Description:
They will walk downhill for 20 minutes at a -(negative)7.5% gradient.
Treatment:
Procedure: Downhill walking
-%15 Downhill walking
Experimental group
Description:
They will walk downhill for 20 minutes at a -(negative)15% gradient.
Treatment:
Procedure: Downhill walking

Trial contacts and locations

1

There are currently no registered sites for this trial.

Central trial contact

Burak Yıldız, Dr.; Özge Keniş Coşkun, MD

Timeline

Last updated: Apr 27, 2023

Start date

Apr 24, 2023 • 2 years ago

End date

May 24, 2023 • 1 year and 11 months ago

Today

May 07, 2025

Sponsor of this trial

Lead Sponsor

Data sourced from clinicaltrials.gov